Schedule an Appointment


Please Read Our Disclaimer

The investment opportunities below are not an offer to the general public to purchase any form of securities. Every investment opportunity below should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the investment opportunities listed on this site. The information contained in these investment opportunities is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors in order to evaluate the investment opportunities and should not be used for any other reason or made available to any other person or entity without the prior written consent of The OCMX (P2P Financial Inc.). The technology and process used on this website is protected by existing or pending patents owned by The OCMX. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Book a Conference Call
Get More Information

Resverlogix Corp.

Location: Calgary, Alberta Sector: Life Science .
Add to Shortlist
Express Interest

Resverlogix Corp. is a Calgary and San Francisco based clinical stage biotechnology company focused primarily on the development of apabetalone. Apabetalone (RVX 208) is a first-in-class small molecule selective BET bromodomain inhibitor, which acts via an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high risk CVD patients with type 2 DM and low high density lipoprotein (HOL) and is expected to be initiated in a Phase 2a kidney dialysis trial.

Business Documents

MG cp Summary

Late Stage Human Clinical Trials  – Resverlogix is focused on significant unmet need in high-risk CVD, diabetes and CKD patient populations, with a phase 3 human clinical trial (BETonMACE) in high risk CVD.


Advanced R&D – Resverlogix’s in-depth understanding of BET inhibitors and world-class medicinal chemistry allows it to develop candidates with better specificity, which affords the opportunity to target chronic disease through the BET pathway.


Market Leader Targeting Significant Unmet Need – Apabetalone is expected to be indicated in several high-risk patient groups totaling over 10M patients in the top seven markets (US, 5EU and Japan).


Established Safety Profile – Over 1,400 patients have been treated to date with apabetalone with no significant safety issues.


Novel Mechanism of Action – Regulation of gene transcription, the turning on or off of various disease-causing genes (unlike the CRISPR approach of changing DNA).


Quality Investor Base – Proven track record of attracting high quality and long term institutional investors

Resverlogix is developing apabetalone, its lead compound, and other compounds that specifically bind the bromodomains of BET proteins. In binding to these bromodomains, these compounds affect the expression of multiple genes with roles in multiple cellular processes that underlie disease. Apabetalone, is currently in phase 3 human clinical trials in 13 countries worldwide and Resverlogix’s platform features other promising follow-on compounds.


Utilizing its knowledge of BET proteins and epigenetics, Resverlogix has identified small molecule candidates with the following characteristics:
–Function via selective inhibition of BET proteins
–Alter the activity of genes that play a key role in disease in relevant cell models
–Demonstrated preclinical and clinical activity against disease targets



DONALD J. MCCAFFREY, President & CEO/Co-Founder

Co-founder, strategic leader and organizational mentor of the company
Over 35 years of business experience including 18 years of drug discovery & development
Personally raised over $300 million for research and clinical development in the areas of CVD, diabetes, CKD, orphan diseases and other indications of high unmet need


DR. EWELINA KULIKOWSKI, Ph.D, Senior Vice President of Research & Development

Over 12 years experience in scientific research and drug development
Involved in the development of apabetalone (RVX-208) from its discovery through to the IND and into clinical development
Doctorate in Oncology from the University of Calgary in 2004


DR. MICHAEL SWEENEY, MD, Senior Vice President of Clinical Development

Over 26 years in the pharmaceutical industry
11 years at Pfizer Inc
CMO and VP of Research and Development at Depomed
VP Medical Affairs at CV Therapeutics, Inc


DR. ELDON R. SMITH, OC, MD, FRCPC, FCAHS, FAHA, FIACS Board of Directors Lead Director

Published more than 250 papers and book chapters
Former Dean of the Faculty of Medicine at the University of Calgary
Former Editor-in-Chief of the Canadian Journal of Cardiology
Past President of the Canadian Cardiovascular Society and the Association of Canadian Medical Colleges, Vice President of the Inter-American Society of Cardiology.